Mendus AB: Direktsänd webbpresentation för att diskutera kliniska resultat från ADVANCE II-studien som presenteras vid ASH 2022
07 déc. 2022 02h00 HE
|
Mendus AB
Mendus AB (”Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier som tar sig an tumörrecidiv, kommer att hålla en direktsänd webbpresentation för att gå igenom företagets...
Mendus AB: Live webcast to discuss clinical results of ADVANCE II trial presented at ASH 2022
07 déc. 2022 02h00 HE
|
Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will host a live webcast to review the Company’s most recent clinical results of...
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
13 juin 2022 07h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...
Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling
16 mai 2022 02h00 HE
|
Immunicum AB
Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd,...
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
16 mai 2022 02h00 HE
|
Immunicum AB
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a...
Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population
14 mars 2022 09h42 HE
|
Impulse Dynamics
MARLTON, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the first...
Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studien
03 déc. 2021 02h00 HE
|
Immunicum AB
Pressmeddelande 3 december 2021 Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studienImmunicum AB (“Immunicum”, publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på...
Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study
03 déc. 2021 02h00 HE
|
Immunicum AB
Press Release Stockholm, Sweden, December 3, 2021 Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical...
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
01 déc. 2021 07h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2,...
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
29 nov. 2021 07h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2,...